General Information of Drug (ID: DMKVXYS)

Drug Name
FK-409 Drug Info
Synonyms nor-3; 3-Hexenamide, 4-ethyl-2-(hydroxyimino)-5-nitro-; 92454-83-6; 163180-49-2; ACMC-20eif3; AC1OAT8P; 4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide; CTK3H0114; CTK4D1460
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Phase 2 [1]
Cross-matching ID
PubChem CID
6413529
CAS Number
CAS 92454-60-9
TTD Drug ID
DMKVXYS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Riociguat DMXBLMP Chronic thromboembolic pulmonary hypertension Approved [3]
Vericiguat DM7MDBE Heart failure BD10-BD13 Approved [4]
BAY412272 DM0M59T Discovery agent N.A. Investigative [5]
ODQ DMSAJO8 Discovery agent N.A. Investigative [6]
NS 2028 DML0N7D Discovery agent N.A. Investigative [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Soluble guanylyl cyclase (GUCY2D) TTWNFC2 GUC2D_HUMAN Modulator [2]

References

1 The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation. Anesth Analg. 1998 Feb;86(2):367-73.
2 Vasorelaxant mechanism of the new vasodilator, FK409. Eur J Pharmacol. 1993 Aug 15;246(3):205-12.
3 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
5 NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001 Mar 8;410(6825):212-5.
6 Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995 Aug;48(2):184-8.
7 Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998 Jan;123(2):299-309.